Candita Thompson, NP
Acute Care · New Orleans, LANPI 1558466847
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 94 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by GSK at 26.0% of the total. Reporting peaked in 2023 at $960 and has fallen 68.1% since, to $306 in 2024.
Across 94 payments — averaging $25.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$635
- Boehringer Ingelheim$285
- Novo Nordisk$229
- AstraZeneca$194
- AbbVie$140
- Johnson & Johnson$136
- plus $818 from 13 others
What the payments were for
- Food & beverage$2,437100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 30 | $635 |
| Boehringer Ingelheim | 4 | $285 |
| Novo Nordisk | 8 | $229 |
| AstraZeneca | 5 | $194 |
| AbbVie | 2 | $140 |
| Johnson & Johnson | 2 | $136 |
| Lilly USA, LLC | 8 | $134 |
| Abbott | 6 | $114 |
| Pfizer | 6 | $104 |
| E.r. Squibb & Sons, L.L.C. | 5 | $102 |
| Exact Sciences | 4 | $94 |
| Esperion Therapeutics, Inc. | 4 | $70 |
| Mannkind Corporation | 1 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Merck | 2 | $37 |
| Amgen | 1 | $19 |
| Novartis | 1 | $17 |
| Bayer | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,437 in reported general payments places this provider in the 80th percentile of 248 acute care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 90 | $76,704 |
| OzempicSemaglutide | 54 | $59,485 |
| MounjaroTirzepatide | 52 | $59,287 |
| JardianceEmpagliflozin | 35 | $36,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $23,171 |
| LinzessLinaclotide | 17 | $18,313 |
| EliquisApixaban | 20 | $18,297 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $5,750 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $4,330 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,053 |
| Fluticasone Propionate | 138 | $2,026 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $1,699 |
| Gabapentin | 104 | $1,479 |
| Rosuvastatin Calcium | 210 | $1,280 |
| Cyproheptadine Hcl | 67 | $1,268 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $37 | $76,70490 claims |
| Novo NordiskOzempic | $229 | $59,48554 claims |
| Lilly USA, LLCMounjaro | $134 | $59,28752 claims |
| Boehringer IngelheimJardiance | $285 | $36,58435 claims |
| GSKTrelegy Ellipta | $635 | $23,17129 claims |
| AbbVieLinzess | $140 | $18,31317 claims |
| PfizerEliquis | $104 | $18,29720 claims |
| AstraZenecaSymbicort | $194 | $5,75024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 248 acute care providers in Louisiana.
Other acute care in New Orleans
- Charles JarreauNew Orleans$40K
- Anita RichardNew Orleans$7K
- Erica LoveNew Orleans$2K
- Annie StadstadNew Orleans$2K
- Jennifer FlemingNew Orleans$2K
- Travis KingNew Orleans$2K
- Precious HodgesLafayette$70K
- Brinton FegleyShreveport$61K
- Jeremy DavisShreveport$35K
- Heather MecomShreveport$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.